Member Info for 60601971

BAE Systems is forecasting strong 2026 sales growth of 7% to 9% and underlying earnings per share (EPS) to rise between 9% and 11%, underpinned by a record order backlog of £83.6 billion. The defense giant's financial position remains robust, continuing to drive shareholder returns via dividends and share buybacks.

I've just eaten an marks and sparks paella washed down with a little vino sitting at my breakfast bar whilst watching the news! Who gives a shiiiit no one does .........

You know nothing!

Stay in Vietnam and stew in your own juices not that you needed to tell us you ride a bike play chess have a son! Lol lol laugh my arse off

You sad Waanker

Don't bother we don't have any respect for what you have to say what so ever

For you and your issues? Yes I'd 2nd a clinical trial

Do you feel better now!?,don't forget to breath!

In through the nose out through the garbage trap!

Mms are corrupt on a false drop and we are worth multiples of what tosh they print

It's never been on aim only aquis and otc

Ananda developments on aquis

You really are some kind of low life to come on here purely to insult

Brilliant Brilliant Brilliant

Already with Jazz and the re occurring revenues with epidolex so let's see what endometriosis does as a comparable move treading in those same footsteps!

Not without risk of course but staggering returns on success. #end game

Supported financially with our trials externally and also have received 1 part of 2 tax relief payment also on our pk study too, so it's a clever business model whilst retaining all IP despite external funding!

Market Access and Monopoly: FDA approval is a prerequisite for a medicine to be legally marketed and sold in the U.S.. It allows the company to secure a potentially long-term, professional market position, often with a period of market exclusivity before generic competitors can enter.

Significant Revenue Potential: A successful new drug can generate substantial revenue, allowing companies to recover their massive R&D investments and generate significant profits.

Increased Investor Confidence: The announcement of FDA approval significantly increases shareholder wealth, as it signals a high probability of a profitable product coming to market.

Enhanced Reputation and Standing: Successfully navigating the complex and stringent FDA process enhances a company's standing as an innovative and capable entity within the scientific and medical community.

Incentives for Innovation: The potential for high rewards encourages pharmaceutical companies to invest in innovative research, particularly for conditions with unmet medical needs, as the FDA offers expedited pathways for such drugs.

Https://www.marijuanamoment.net/federal-health-agency-moves-to-allow-cbd-coverage-under-medicare-as-promoted-in-video-trump-posted/

That one

After the over done drop by the mms which was criminal

No brainer

Https://mjbizdaily.com/ananda-pharma/

We delist and crack on at lower operational costs opening up easier doors to knock on to finance with solid backing as always from our chairman whos got 10million proof in the pudding with mrx1 trial results on the brink to prove current value is way way to low! That's what I have to say